PubRank

Jean-Marie Poirier

Author PubWeight™ 8.97‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir. J Acquir Immune Defic Syndr 2006 1.42
2 Atazanavir urinary stones in an HIV-infected patient. AIDS 2006 0.91
3 High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 2003 0.90
4 Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 2005 0.88
5 Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS 2009 0.85
6 Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results. AIDS 2013 0.85
7 Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. AIDS 2010 0.82
8 Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors. AIDS 2006 0.80
9 Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir. J Int Assoc Physicians AIDS Care (Chic) 2008 0.79
10 Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. J Antimicrob Chemother 2009 0.78
11 Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial. J Antimicrob Chemother 2010 0.75
12 [Evidence-based therapeutic drug monitoring for indinavir]. Therapie 2011 0.75
13 Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS 2005 0.75
14 Effects of malnutrition on cytochrome P450 1A2 activity in elderly patients. Therapie 2004 0.75
15 [Evidence-based therapeutic drug monitoring of lopinavir]. Therapie 2011 0.75